| Předmět: |
|
| Zdroj: |
Drug Week; 1/5/2024, p1165-1165, 1p |
| Abstrakt: |
A study conducted by researchers at Alma Mater Studiorum - University of Bologna has provided new data on eczema and its clinical associations. The study focused on cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) in patients with cancer. The researchers found that there were 40 different types of skin toxicities identified, with psoriasis and pruritus being the most common. The study also revealed that the specific agent administered and the underlying malignancy treated were factors that influenced the development of skin toxicities. The researchers concluded that follow-up plans should be individualized to minimize the risk of severe reactions. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
